Events
 |
Moving Beyond the Tuberculin Skin Test (TST) (also known as the Mantoux Test)
Find out why this century-old test is no longer highly effective for the needs of the 21st century. Learn what the other options for TB screening are and the pros and cons of these different tests. |
 |
Expert Series: What is the Borderline? (Part 1)
Dr. Juzar Ali discusses the T-SPOT®.TB test’s Borderline result category and its clinical utility in helping to reduce the risk of misclassifying patients whose results are around the test’s established cut-offs for Positive or Negative. This video discusses the utility and significance of the T-SPOT.TB test’s Borderline result category. |
 |
Expert Series: What is the Borderline? Case Studies (Part 2)
Dr. Juzar Ali presents three patient case studies to illustrate the importance of the T-SPOT®.TB test’s Borderline result category in clinical scenarios. |
 |
Diagnosing TB in the Immunocompromised: What’s New?
The risk of progression from Latent TB infection (LTBI) to active TB is higher amongst immunocompromised patients — who are they? Webinar covers an update on TB testing methods amongst immunocompromised patients and the clinical utility of IGRAs in this patient population group. |
 |
Expert Series: FAQS to Diagnosing TB in the Immunocompromised (Part 1)
LTBI Testing Methodologies: Dr Roy Chemaly answers Frequently Asked Questions (FAQs) about diagnosing Latent TB infection (LTBI) in immunocompromised patient populations. |
 |
Expert Series: FAQS to Diagnosing TB in the Immunocompromised (Part 2)
Immunocompromised Patient Population: Dr. Roy Chemaly answers Frequently Asked Questions (FAQs) about diagnosing Latent TB infection (LTBI) in immunocompromised patient populations. |
Page : 1 | 2 | Next
 The Oxford Educational Series A new series of live educational talks intended to inform attendees about the current thinking in TB and COVID-19, and enable them to keep up to date with the latest developments. |